Search

CMSC Abstracts View

Search Accepted Abstracts
Sending

Search Results

Year ID Type Category Title Authors
2018 DX36 Poster Disease-Modifying Therapy

Transition from Natalizumab to Dimethyl Fumarate in Multiple Sclerosis Patients: Clinical and MRI Outcomes

Mark Waheed, DO, John W Rose, MD, Ka-ho Wong, BS, Stacey Clardy, MD PhD, Julia Klein, APRN, M. Mateo Paz Soldan, MD PhD, Lucy D Dewitt, MD and John Steffens, MD, Neurology, University of Utah School of Medicine, Salt Lake City, UT

2018 DX37 Poster Disease-Modifying Therapy

Moderate-to-Vigorous Physical Activity Is Positively Associated with the Retinal Nerve Fibre Layer Thickness in Pediatric Multiple Sclerosis

Alexander L Pearson, BA1, Stephanie A Grover, MSc, CCRP2, Danusha Nandamalavan, BSc, CCRA2, Tara Berenbaum, BSc3, Robert W Motl, PhD4, Marcia Finlayson, PhD, OT Reg (Ont), OTR5, Brenda Banwell, MD6 and E. Ann Yeh, MD, MA, FRCPC, Dip ABPN3, (1)Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada, (2)Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON, Canada, (3)Neurology, The Hospital for Sick Children, Toronto, ON, Canada, (4)Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (5)School of Rehabilitation Therapy, Queen’s University, Kingston, ON, Canada, (6)Children’s Hospital of Philadelphia, Philadelphia, PA

2018 DX38 Poster Disease-Modifying Therapy

Life-Threatening Tumefactive Rebound of Multiple Sclerosis Following Fingolimod Discontinuation

Mihir Kakara, M.D., Jay Kinariwala, M.D., Shitiz K Sriwastava, M.D. and Evanthia Bernitsas, MD, Neurology, Wayne State University School of Medicine, Detroit, MI

2018 DX39 Poster Disease-Modifying Therapy

Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis

2018 DX40 Poster Disease-Modifying Therapy

An Update on Pregnancy Outcomes Following Ocrelizumab Treatment in Patients with Multiple Sclerosis and Other Autoimmune Diseases

Sibyl Wray, MD1, Ludwig Kappos, MD2, Sandra Vukusic, MD, PhD3, Silvia Bader-Weder, MD4, Regine Buffels, MD4, Donna Masterman, MD, MS5, Julie Napieralski, PhD4 and Stephen L Hauser, MD6, (1)Sibyl Wray MD Neurology PC, Knoxville, TN, (2)Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Basel, Switzerland, (3)Service de Neurologie et Sclerose en Plaques, Fondation EDMUS pour la Sclerose en Plaques, Hopital Neurologique Pierre Wertheimer, Lyon, France, (4)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (5)Genentech Inc., South San Francisco, CA, (6)University of California, San Francisco, San Francisco, CA

2018 DX41 Poster Disease-Modifying Therapy

Routine Laboratory Measures in the Controlled Treatment Period of Phase III Ocrelizumab Trials in Relapsing and Progressive Multiple Sclerosis

2018 DX42 Poster Disease-Modifying Therapy

Prespecified Subgroup Analyses of Ocrelizumab Efficacy in Patients with Primary Progressive Multiple Sclerosis from the Phase III ORATORIO Study

Jerry S Wolinsky, MD1, Xavier Montalban, MD, PhD2,3, Stephen L Hauser, MD4, Ludwig Kappos, MD5, Laura Julian, PhD6, Marianna Manfrini, MD PhD7, Shibeshih Belachew, MD, PhD7, Fabian Model, PhD7, Stanislas Hubeaux, MSc7 and Amit Bar-Or, MD8, (1)McGovern Medical School, UTHealth, Houston, TX, (2)Division of Neurology, University of Toronto, Toronto, ON, Canada, (3)Vall d’Hebron University Hospital, Barcelona, Spain, (4)University of California, San Francisco, San Francisco, CA, (5)University Hospital Basel, University of Basel, Basel, Switzerland, (6)Genentech, Inc., South San Francisco, CA, (7)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (8)University of Pennsylvania, Philadelphia, PA

2018 DX43 Poster Disease-Modifying Therapy

Effect of Ocrelizumab on Vaccine Responses in Patients with Multiple Sclerosis

Daniela Stokmaier, MSc Pharm PhD1, Kevin Winthrop, MD MPH2, Cathy Chognot, PhD3, Joanna Evershed, BSc4, Marianna Manfrini, MD PhD3, John McNamara, BSc MSc CStat5 and Amit Bar-Or, MD6, (1)F.Hoffmann-La Roche Ltd, Basel, Switzerland, (2)Division of Infectious Diseases, OHSU, Portland, OR, (3)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (4)Roche Products Ltd, Welwyn Garden City, United Kingdom, (5)John McNamara Consulting Limited, Cambridge, United Kingdom, (6)University of Pennsylvania, Philadelphia, PA

2018 DX44 Poster Disease-Modifying Therapy

Pregnancy Outcomes in Patients with MS Treated with Teriflunomide: Postmarketing Data

Patricia K Coyle, MD1, Sandra Vukusic, MD, PhD2, Stephanie Jurgensen, MPH3, Philippe Truffinet, MD4, Myriam Benamor, MD4, Elizabeth Poole, PhD3, Jeffrey Chavin, MD3 and Christina Chambers, PhD5, (1)Stony Brook University, Stony Brook, NY, (2)University Hospital of Lyon, Lyon, France, (3)Sanofi, Cambridge, MA, (4)Sanofi, Chilly-Mazarin, France, (5)University of California San Diego, La Jolla, CA

2018 DX45 Poster Disease-Modifying Therapy

Brain MRI Activity and Atrophy in Ocrelizumab-Treated Relapsing Multiple Sclerosis Patients in the Open-Label Extension of the Pooled Opera Trials

2018 DX46 Poster Disease-Modifying Therapy

Infusion-Related Reactions with Ocrelizumab in the Phase III Studies

2018 DX47 Poster Disease-Modifying Therapy

Effect of Long-Term Teriflunomide Treatment on Lymphocyte Counts and Infection Rates in Pooled Data from TEMPSO, TOWER, and TOPIC Core and Extension Studies

Aaron E Miller, MD1, Giancarlo Comi, MD2, Myriam Benamor, MD3, Philippe Truffinet, MD3, Karthinathan Thangavelu, PhD4, Jeffrey Chavin, MD4 and Mark S Freedman, MD5, (1)Icahn School of Medicine at Mount Sinai, New York, NY, (2)University Vita-Salute San Raffaele, Milan, Italy, (3)Sanofi, Chilly-Mazarin, France, (4)Sanofi, Cambridge, MA, (5)University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada

2018 DX48 Poster Disease-Modifying Therapy

Effect of Teriflunomide on Substantial Disability Worsening in Patients with Relapsing Forms of MS in the Phase 3 TOWER Study

Mark S Freedman, MD1, Aaron E Miller, MD2, Elizabeth Poole, PhD3, Jeffrey Chavin, MD3, Philippe Truffinet, MD4 and Ludwig Kappos, MD5, (1)University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, (2)Icahn School of Medicine at Mount Sinai, New York, NY, (3)Sanofi, Cambridge, MA, (4)Sanofi, Chilly-Mazarin, France, (5)Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Basel, Switzerland

2018 DX50 Poster Disease-Modifying Therapy

Ocrelizumab Pregnancy Registry to Assess Maternal, Fetal and Infant Outcomes in Women with Multiple Sclerosis Exposed to Ocrelizumab during Pregnancy

David Wormser, MSc, MPhil PhD1, Pierre Engel, PharmD, MPH, PhD2, Kristen Hahn, MPH, PhD3, Silvia Bader-Weder, MD1, Eva-Maria Didden, PhD1, Joanna Evershed, BSc4, Monika Garas, PhD1, Qing Wang, PhD1 and Kerstin Hellwig, PhD MD5, (1)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (2)QuintilesIMS, Paris, France, (3)QuintilesIMS, Cambridge, MA, (4)Roche Products Ltd, Welwyn Garden City, United Kingdom, (5)St. Josef-Hospital, Ruhr University, Bochum, Germany

2018 DX51 Poster Disease-Modifying Therapy

Post-Marketing Study to Evaluate Pregnancy and Infant Outcomes in Women with Multiple Sclerosis Exposed to Ocrelizumab during Pregnancy

Andrea V Margulis, MD ScD1, Elizabeth B Andrews, PhD MPH2, Sonia Hernandez-Diaz, MD DrPH3, Melinda Magyari, MD PhD4, Elena Rivero-Ferrer, MD MPH1, Silvia Bader-Weder, MD5, Joanna Evershed, BSc6, Monika Garas, PhD5, Qing Wang, PhD5 and David Wormser, MSc, MPhil PhD5, (1)RTI Health Solutions, Barcelona, Spain, (2)RTI Health Solutions, Research Triangle Park, NC, (3)Harvard University, Boston, MA, (4)Danish Multiple Sclerosis Center, Copenhagen University Hospital, Copenhagen, Denmark, (5)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (6)Roche Products Ltd, Welwyn Garden City, United Kingdom

2018 DX52 Poster Disease-Modifying Therapy

Efficacy Outcomes in Patients Randomized to Fingolimod or Injectable Disease-Modifying Therapies in PREFERMS: Effect of Previous Treatment Cycles

Samuel F Hunter, MD1, Florian P Thomas, MD, PhD, MA2,3, Xiangyi Meng, PhD4, Lesley Schofield, PhD4, Scott Kolodny, MD4, Nadia Tenenbaum, MD4 and Bruce AC Cree, MD, PhD5, (1)Advanced Neurosciences Institute, Franklin, TN, (2)Seton Hall-Hackensack Meridian School of Medicine, South Orange, NJ, (3)Neurology, Hackensack University Medical Center, Hackensack, NJ, (4)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (5)UCSF Neurology, Weill Institute for Neurosciences, San Francisco, CA

2018 DX53 Poster Disease-Modifying Therapy

Changes in Whole Brain Volume and Cortical Gray Matter over 2 Years of Natalizumab Treatment: Results from the STRIVE Study

Jai Perumal, MD1, Robert J Fox, MD2, Roumen Balabanov, MD3, Laura J Balcer, MD, MSCE4, Steven Galetta, MD4, Shavy Makh, MPhil5, Sourav Santra, PhD5, Elizabeth Fisher, PhD5, Christophe Hotermans, MD, PhD5 and Lily Lee, MD5, (1)Judith Jaffe Multiple Sclerosis Center, New York, NY, (2)Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, (3)Northwestern University, Chicago, IL, (4)New York University Langone Medical Center, New York, NY, (5)Biogen, Cambridge, MA

2018 DX54 Poster Disease-Modifying Therapy

Review of Immunization Status of Patients Switched to Ocrelizumab: A Tertiary Care Experience

Lakshman Arcot Jayagopal, MD, Deb Cramer, RN, BSN, MSCN, Wendy Durand, RN BSN, Deborah Gallaro, RPH, Bren Hammond, RN, BSN, MSCN, Michael Persenaire, MD, Gary Stobbe, MD, Jennie Toro, RN, Gloria von Geldern, MD and Annette Wundes, MD, University of Washington, Seattle, WA

2018 DX55 Poster Disease-Modifying Therapy

Real-World Characterization of Flu-like Symptom Severity and Duration in Patients with RMS: Interim Analysis of the Peginterferon Beta-1a Pop Study

Maria L Naylor, PhD1, Marco Salvetti, MD2, Jang Yun, MS, PhD1, Craig Wakeford, MA1 and Sibyl Wray, MD3, (1)Biogen, Cambridge, MA, (2)Sapienza University, Sant’ Andrea Hospital, Rome, Italy, (3)Hope Neurology MS Center, Knoxville, TN

2018 DX56 Poster Disease-Modifying Therapy

The Importance of Pharmacist Involvement in Laboratory Adherence for Patients on Disease Modifying Therapy for Multiple Sclerosis, Utilizing a Clinical Dashboard

Dante M Grassi, Pharm D., BCPS, Enterprise Pharmacy, Center for Pharmacy Innovation and Outcomes, Geisinger, Danville, PA, Amanda Sharry-Rogers, Pharm D., BCPS, Enterprise Pharmacy, Geisinger, Wilkes-Barre, PA, Ashley L Lauver, Pharm D., Enterprise Pharmacy, Geisinger, Danville, PA, Douglas C Nathanson, MD, Neuroscience, Geisinger, Wilkes-Barre, PA, Joseph J Chronowski, MBA, BA, Care Support Services, Geisinger, Danville, PA and Jove Graham, PhD, Center for Pharmacy Innovation and Outcomes, Geisinger, Danville, PA

2018 DX57 Poster Disease-Modifying Therapy

Potential Infectious Complications of B-Cell Depleting Therapies-a Focus on Rituximab in Multiple Sclerosis

Cindy Darius, MS, RN1, Maureen A. Mealy, PhD(c), RN2, Megan Esch, MD3, Salman Aljarallah, MBBS FRCPC4, Kathleen Costello, MS, ANP-BC, MSCN5, Lisa Fox, PA-C MPAS4 and Shiv Saidha, MBBCh6, (1)Neurology, Johns Hopkins School of Medicine, Balitmore, MD, (2)Acute and Chronic Care, Johns Hopkins University School of Nursing, Baltimore, MD, (3)Neurology, The Johns Hopkins School of Medicine, Baltimore, MD, (4)Neurology, Johns Hopkins School of Medicine, Baltimore, MD, (5)Vice President, Healthcare Access, National Multiple Sclerosis Society, New York, NY, (6)Neurology, Johns Hopkins University, Baltimore, MD

2018 DX58 Poster Disease-Modifying Therapy

Baseline Cognitive Function of Patients with Relapsing Remitting Multiple Sclerosis Is Associated with Therapeutic Response to Natalizumab

Daniel Golan, MD1, Mark Gudesblatt, MD2, Karl Wisseman, N/A2, Myassar Zarif, MD2, Barbara Bumstead, MS, ANCP, MSCN2, Lori Fafard, RN, BSN, CNRN, MSCN, CCRP2, Cynthia Sullivan, PhD3, Jeffrey Wilken, PhD4, Jared Srinivasan, N/A2, Karen Blitz, DO2, Marijean Buhse, PhD, NP, RN, MSCN5 and Glen Doniger, PhD6, (1)Rapparport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel, (2)South Shore Neurologic Associates, Patchogue, NY, (3)Nursing, State University of New York @ Stony Brook, Stony Brook, NY, (4)Washington Neuropsychology Research Group, Washington, DC, (5)Stony Brook University, Stony Brook, NY, (6)NeuroTrax Corporation, Modiin, Israel

2018 DX59 Poster Disease-Modifying Therapy

Characterization of the Hispanic MS Patient on Alemtuzumab

Angel Chinea, MD1, Ivonne Vicente, MD2, Cristina M Rubi, BS2, Allan J Reyes, BA3, Astrid Diaz, BS4 and Genesis Burgos, HS5, (1)San Juan Multiple Sclerosis Center, San Juan, PR, (2)San Juan Multiple Sclerosis Center, Guaynabo, PR, (3)Neurology, San Juan MS Center, Guaynabo, PR, Puerto Rico, (4)San Juan MS Center, Guaynabo, PR, (5)San Juan MS Center, Guaynabo, PR, Puerto Rico

2018 DX60 Poster Disease-Modifying Therapy

Leflunomide for the Treatment of Multiple Sclerosis: A Case Series

Daniel Kantor, MD1,2, Asya I. Wallach, MD3, Samuel F Hunter, MD4, Christopher W. Milligan, MS, PA-C4, Ajay S Gupta, MD5, Richard A. Sater, MD, PhD6, Marcus Rice, MD7 and Ilya Kister, MD3, (1)Medical Partnership 4 MS (MP4MS), Coconut Creek, FL, (2)Florida Atlantic University, Boca Raton, FL, (3)MS Comprehensive Care Center, NYU School of Medicine, New York, NY, (4)Advanced Neurosciences Institute, Franklin, TN, (5)Fort Wayne Neurological Center, Fort Wayne, IN, (6)Guilford Neurological Associates, Greensboro, NC, (7)Neurology Specialists, Norfolk, VA

2018 DX61 Poster Disease-Modifying Therapy

Fingolimod and Cryptococcus: A Reminder of the Intersection between Immunomodulation and Infectious Disease

Rohini D Samudralwar, MD and Ann Cross, MD, Neurology, Washington University in St. Louis, St.Louis, MO

2018 DX62 Poster Disease-Modifying Therapy

6 Month Results from a Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS), Demonstrates Complete Elimination of Gd-Enhancing Lesions

Matilde Inglese, MD, PhD1, Maria Petracca, MD, PhD2, Sirio Cocozza, MD2, Sibyl Wray, MD3, Michael K Racke, MD4, Richard Shubin, MD5, Cary L Twyman, MD6, Wendy Su, PhD7, James Eubanks, PhD7, Koby Mok, PhD7, Michael Weiss, JD7 and Edward J. Fox, MD, PhD8, (1)Department of Neurology, Radiology and Neuroscience, Mount Sinai School of Medicine, New York, NY, (2)Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, (3)Hope Neurology MS Center, Knoxville, TN, (4)Wexner Medical Center, Ohio State University, Columbus, OH, (5)SC3 Research Group, Inc, Pasadena, CA, (6)Associates in Neurology PSC, Lexington, KY, USA, Lexington, KY, (7)Autoimmune, TG Therapeutics, Inc, New York, NY, (8)Central Texas Neurology Consultants, Round Rock, TX

2018 DX63 Poster Disease-Modifying Therapy

Myelin Water Fraction As a Potential Marker of Progression in Primary Progressive Multiple Sclerosis

Kimberley Chang, .1, Irene Vavasour, PhD1, Roger Tam, .1, David Clayton, .2, Victoria Levesque, PhD2, David Li, MD, FRCPC1, Anthony Traboulsee, MD1 and Shannon Kolind, PhD1, (1)University of British Columbia, Vancouver, BC, Canada, (2)Genentech, Inc., South San Francisco, CA

2018 EG01 Poster Epidemiology and Genetics

National Estimates of Self-Reported Sitting Time in Adults with Multiple Sclerosis

Jeffer E Sasaki, PhD1, Robert W Motl, PhD1, Gary Cutter, PhD2, Ruth A Marrie, PhD3, Tuula Tyry, PhD4 and Amber Salter, PhD5, (1)Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (2)University of Alabama at Birmingham, Birmingham, AL, (3)Department of Internal Medicine (Neurology), University of Manitoba, Winnipeg, MB, Canada, (4)Dignity Health, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, (5)Washington University in St Louis, St Louis, MO

2018 EG02 Poster Epidemiology and Genetics

Validity of the Marshall Sitting Questionnaire in Persons with Multiple Sclerosis

Jeffer E Sasaki, PhD1, Robert W Motl, PhD1 and Edward McAuley, PhD2, (1)Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (2)Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL

2018 EG03 Poster Epidemiology and Genetics

Factors Associated with Excessive Sitting Time in Multiple Sclerosis

Jeffer E Sasaki, PhD1, Robert W Motl, PhD1, Gary Cutter, PhD2, Ruth A Marrie, PhD3, Tuula Tyry, PhD4 and Amber Salter, PhD5, (1)Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (2)University of Alabama at Birmingham, Birmingham, AL, (3)Department of Internal Medicine (Neurology), University of Manitoba, Winnipeg, MB, Canada, (4)Dignity Health, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, (5)Washington University in St Louis, St Louis, MO

2018 EG04 Poster Epidemiology and Genetics

Prevalence of Comorbidities in Patients with and without Multiple Sclerosis By Age and Sex: A US Retrospective Claims Database Analysis

Kiren Kresa-Reahl, MD, dence Multiple Sclerosis Center and Providence Center for Parkinson’s Disease, Portland, OR, Natalie C Edwards, MSc, Health Services Consulting Corporation, Boxborough, MA and Amy L Phillips, PharmD, EMD Serono, Inc., Rockland, MA

2018 EG05 Poster Epidemiology and Genetics

Mood Disorders in Multiple Sclerosis: About 100 Patients Collected in the Service of Neurology University Hospital of Tlemcen (ALGERIA)

Bouchenak Khelladi Djaouad Sr., Professor, Neurology, University of Medecine, Tlemcen, Algeria

2018 EG06 Poster Epidemiology and Genetics

The Current Situation of the Multiple Sclerosis in the Department of Tlemcen (ALGERIA)

Bouchenak Khelladi Djaouad Sr., Professor, Neurology, University of Medecine, Tlemcen, Algeria

2018 EG07 Poster Epidemiology and Genetics

Epidemiological Evaluation of People with Multiple Sclerosis in Brazil

Ana Maria Canzonieri, psychologist1, Thais Mira Simandi, Psychology student2 and Dyana Gervana de Oliveira Fernandes, biomedicine student1, (1)Pesquisa cientifica, ABEM – Brazilian Association of Multiple Sclerosis, Sao Paulo, Brazil, (2)Pesquisa cientifica, ABEM – Brazilian Association of Multiple Sclerosis, sAO pAULO, Brazil

2018 EG08 Poster Epidemiology and Genetics

Validation of the Symptomscreen with Objective Clinical Outcome Measures

Kathryn C Fitzgerald, ScD, Johns Hopkins School of Medicine, Baltimore, MD, Amber Salter, PhD, Washington University in St Louis, St Louis, MO, Tuula Tyry, PhD, Dignity Health, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, Robert J Fox, MD, Cleveland Clinic, Cleveland, OH, Gary Cutter, PhD, University of Alabama at Birmingham, Birmingham, AL and Ruth Ann Marrie, MD, PhD, University of Manitoba, Winnipeg, MB, Canada

2018 EG09 Poster Epidemiology and Genetics

Overview of the North American Registry for Care and Research in MS (NARCRMS)

Kottil Rammohan, MD1, David Jones, MD2, June Halper, MSN, ANP, FAAN3, Sara McCurdy Murphy, BA4 and Lisa Patton, BA4, (1)University of Miami, Miami, FL, (2)UVA, Charlottesville, VA, (3)CEO-CMSC, Hackensack, NJ, (4)CRB, Social & Scientific Systems, Inc., Silver Spring, MD

2018 ET01 Poster Ethics

Professionals’ Knowledge and Attitudes about End of Life in MS

Aliza Ben-Zacharia, DNP, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, Francois Bethoux, MD, Department of Rehabilitation Services, Cleveland Clinic Mellen Center, Cleveland, OH and Angelo Volandes, MD, MPH, Palliative Care, Co-Founder & President ACP Decisions, Harvard School of Medicine, Boston, MA

2018 ET02 Poster Ethics

Engaging Minorities with MS in Research: How Patients Learn about and Consider Research Participation

Hollie Schmidt, MS1, Debra I Frankel, MS OTR2, April Moreno, PhD MPA3, Mitzi J Williams, MD4, Lilyana Amezcua, MD, MS5, Shawn Feliciano, B.S.1, Anita Williams, M.S.1, Daniel Machemer, PhD6, Terrie Livingston, PharmD7, Monique LaRocque, MPH8, Melissa Glim, MPH8 and Daniela Pimentel Maldonado, MD9, (1)Accelerated Cure Project for MS, Waltham, MA, (2)Advocacy, Services and Research Department, National Multiple Sclerosis Society, NY, NY, (3)Biomedical Informatics, UCSD School of Medicine, La Jolla, CA, (4)Multiple Sclerosis Center of Atlanta, Atlanta, GA, (5)Neurology, University of Southern California, Los Angeles, CA, (6)Genentech, Inc., South San Francisco, CA, (7)Biogen, Weston, MA, (8)Feinstein Kean Healthcare, Washington, DC, (9)University of Massachusetts Medical School, Worcester, MA

2018 FC01 Poster Family and Caregivers

An Exploratory Study of the Benefit of an Emotionally Focused Therapy Program on the Relationship Quality of Couples Living with Multiple Sclerosis (MS)

Deborah S Lockridge, RN, BSN, MMFT, Norton Healthcare, Louisville, KY

2018 FC02 Poster Family and Caregivers

Identifying the Unmet Needs of Adults with Multiple Sclerosis (MS) Experiencing Cognitive Difficulties and Their Support Partners.

Elizabeth J Halstead, Ph.D, MyHealios, Flemington, NJ, United Kingdom; Health and Social Care, University of Sunderland, London, United Kingdom, Damian Fiore, Pharm.D, Genentech Inc., San Francisco, CA and Kim T Mueser, Ph.D, Center for Psychiatric Rehabilitation, Boston University, Boston, MA; MyHealios, Flemington, NJ